文献速递消化道肿瘤与早癌消化内镜

三项前瞻性队列中间期结直肠癌的临床与基因组特征

Clinical and Genomic Characterization of Interval Colorectal Cancer in 3 Prospective Cohorts.
PubMed 文献 · Gastroenterology · 2022-08-13

研究纳入前列腺、肺、结直肠和卵巢癌筛查试验(PLCO)的1175例结直肠癌及护士健康研究(NHS)与卫生专业人员随访研究(HPFS)的3661例结直肠癌,比较间期结直肠癌与筛查检出结直肠癌的临床与突变特征。间期结直肠癌的结直肠癌特异性死亡风险为筛查检出者的1.47倍(95%CI 1.21-1.78),全因死亡风险为1.27倍(95%CI 1.09-1.47)。全外显子组测序未发现两组间突变特征有显著差异(错误发现率校正P>.05)。

要点

  • 与筛查检出结直肠癌相比,间期结直肠癌的结直肠癌特异性死亡风险升高(HR 1.47,95%CI 1.21-1.78)。
  • 间期结直肠癌的全因死亡风险亦升高(HR 1.27,95%CI 1.09-1.47)。
  • 全外显子组测序未发现间期与筛查检出结直肠癌的突变特征存在显著差异。

核心结论

  • 间期结直肠癌的死亡风险显著高于筛查检出结直肠癌,且该差异无法由包括诊断分期在内的已知临床预后因素解释。
  • 间期结直肠癌的生存劣势似乎不能由全外显子组测序所表征的肿瘤基因组差异来解释。

研究设计与样本

  • 研究纳入PLCO癌症筛查试验的1175例结直肠癌以及NHS和HPFS的3661例结直肠癌。
  • 采用多变量Cox模型估计死亡风险的风险比(HR)和95%置信区间(CI)。
  • 对147例PLCO病例和796例NHS/HPFS病例进行全外显子组测序。

主要发现

  • PLCO随访期间确认619例死亡(其中312例为结直肠癌特异性死亡),NHS/HPFS确认2404例死亡(其中1904例为结直肠癌特异性死亡)。
  • 与筛查检出结直肠癌相比,间期结直肠癌的结直肠癌特异性死亡多变量校正HR为1.47(95%CI 1.21-1.78),全因死亡HR为1.27(95%CI 1.09-1.47)(Meta分析合并全部3个队列)。
  • 未观察到间期与筛查检出结直肠癌在突变特征上有显著差异(错误发现率校正P>.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Interval colorectal cancers (CRCs), cancers diagnosed after a screening/surveillance examination in which no cancer is detected, and before the date of next recommended examination, reflect an unprecedented challenge in CRC detection and prevention. To better understand this poorly characterized CRC variant, we examined the clinical and mutational characteristics of interval CRCs in comparison with screen detected CRCs. METHODS: We included 1175 CRCs documented in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial and 3661 CRCs in the Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS). Multivariable Cox models were performed to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of death risk. Whole exome sequencing was conducted in 147 PLCO cases and 796 NHS/HPFS cases. RESULTS: A total of 619 deaths (312 CRC-specific) and 2404 deaths (1904 CRC-specific) were confirmed during follow-up of PLCO and NHS/HPFS, respectively. Compared with screen detected CRCs, interval CRCs had a multivariate-adjusted HR (95% CI) of 1.47 (1.21-1.78) for CRC-specific mortality and 1.27 (1.09-1.47) for overall mortality (meta-analysis combining all 3 cohorts). However, we did not observe significant differences in mutational features between interval and screen detected CRCs (false discovery rate adjusted P > .05). CONCLUSION: Interval CRCs had a significantly increased risk of death compared with screen detected CRCs that were not explained by established clinical prognostic factors, including stage at diagnosis. The survival disadvantage of interval CRCs did not appear to be explained by differences in the genomic landscape of tumors characterized by whole exome sequencing.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Yang K, Cao Y, Gurjao C, et al. Clinical and Genomic Characterization of Interval Colorectal Cancer in 3 Prospective Cohorts. Gastroenterology. 2022. PMID: 35970241. doi:10.1053/j.gastro.2022.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。